14 October 2015 - The highly-publicized sudden 55-fold spike in the cost of the anti-parasite drug Daraprim has elevated drug pricing to the political realm–with unfortunate consequences.

On September 18, the Center for American Progress, aka “Hillary Clinton’s think tank,” released a plan for “Public- and Private-Sector Reforms to Curb Rising Drug Costs” which largely substitutes the wisdom of bureaucrats and jerry-built price controls for entrepreneurship and markets. Three days later, Mrs. Clinton tweeted, “Price-gouging like this in the specialty drug market is outrageous.” And the NASDAQ Biotechnology Index promptly lost 4 percent of its value.

For more details, go to: http://www.forbes.com/sites/henrymiller/2015/10/14/an-antidote-for-escalating-drug-prices-reciprocity-of-regulatory-approvals/